Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine

TheMotleyFool

0 0

Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) compete head-to-head in the pneumococcal vaccine market. While Pfizer's Prevnar 13 remains the best seller, both companies have newer vaccines on the market. In this Motley Fool Live video recorded on Sept. 29, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Pfizer will profit not just from its new entrant but also from Merck's rival pneumococcal vaccine.

Source Fool.com

Like: 0

PFE

Share